NFSG
LCTX icon

Newbridge Financial Services Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Newbridge Financial Services Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$5 – 1162
2024
Q3 		$5 Hold
5
– – ﹤0.01% 652
2024
Q2 		$5 Hold
5
– – ﹤0.01% 1079
2024
Q1 		$7 Hold
5
– – ﹤0.01% 1169
2023
Q4 		$5 Hold
5
– – ﹤0.01% 1115
2023
Q3 		$6 Hold
5
– – ﹤0.01% 1278
2023
Q2 		$7 Hold
5
– – ﹤0.01% 1342
2023
Q1 		$8 Hold
5
– – ﹤0.01% 1401
2022
Q4 		$6 Hold
5
– – ﹤0.01% 1434
2022
Q3 		$0 Hold
5
– – ﹤0.01% 1433
2022
Q2 		$0 Buy
+5
New +$7 ﹤0.01% 1448

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return